Skip to main content

Market Overview

Incyte To Stop A Phase 2 Sub-Study, Shares Lose 10%


Shares of Incyte Corporation (NASDAQ: INCY) fell more than 10 percent on Thursday after the company said it will stop an ongoing Phase 2 sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP.

According to Incyte's press release, the company decided to stop its study after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy to warrant continuation.

"We are disappointed at the outcome from this interim analysis and deeply grateful for the support and commitment of the patients participating in the study, their families, and the study investigators," said Steven Stein, M.D., Chief Medical Officer of Incyte.


Related Articles (INCY)

View Comments and Join the Discussion!

Posted-In: cancer Cancer Drugs Incyte Ruxolitinib Plus RegorafenibNews Health Care Movers General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at